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U.S. National Commission for the Protection of Human Subjects of Biomedical 
and Behavioral Research, called for a moratorium on prisoner experimentation.6 
These institutions further advocated the development of standards to regulate 
medical experimentation in the prison setting and to safeguard the welfare of 
prisoners who were included in clinical trials. 7 
Subsequently, regulations regarding the use of biomedical experimentation 
on prisoners were issued by the federal government. Department of Health and 
Human Services ("DHHS") regulations8 limit inmate participation in clinical 
investigations to the following: (I) studies of the possible causes, effects, and 
processes of imprisonment and criminal behavior so long as the research involves 
only minimal risk and inconvenience to the subject; (2) studies of prisons as 
institutional entities or of inmates as incarcerated individuals, so long as the 
research involves only minimal risk and inconvenience to the subject; (3) 
research on particular conditions affecting prisoners as a class so long as the 
research is approved by the Secretary of Health and Human Services or an 
authorized DHHS employee ("Secretary"); and ( 4) research involving a treatment 
likely to benefit the prisoner himself or herself.9 In addition, the institutional 
review boardassessing the clinical trial must include at least one prisoner or 
prisoner representative10 and must certify that a variety of conditions have been 
met and that a number of precautions have been taken." As a result of these and 
other stringent requirements, only about fifteen percent of institutions engaging 
in clinical research in the United States include prisoners in their research 
protocols. 12 
Abuse of prisoner subjects in biomedical research or failure to obtain 
meaningful informed consent from inmates can lead to violations of their 
constitutional rights. The constitutional provisions that may be implicated in 
controversies regarding biomedical experimentation on prisoners include the 
Fourth Amendment, Eighth Amendment, and Fourteenth Amendment. 
Nevertheless, prohibiting seriously ill prisoners from participating voluntarily in 
clinical research may constitute an equivalent contravention of their 
constitutional rights under the Eighth Amendment and the Due Process and Equal 
6. See ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056. 
7. See id.; REPORT, supra note 2. 
8. Additional Protections Pertaining to Biomedical and Behavioral Research Involving 
Prisoners as Subjects, 45 C.F.R. § 46.301 (1998). 
9. See 45 C.F.R. § 46.306(a)(2). If a prisoner might be assigned to a placebo control arm, 
the study can proceed only with approval by the Secretary. See id. § 46.306(a)(2)(iv). 
10. See id. § 46.304(b). 
11. See id. § 46.305(c). 
12. Interview with Paula Knudson, Executive Coordinator ofthe University ofTexas Health 
Science Center Committee for the Protection of Human Subjects (Sept. 18, 1998). See also Reid 
J. Schar, Downward Sentencing Departures for HIV-Infected Defendants: An Analysis of Current 
Law and a Framework for the Future, 91 Nw. U. L. REv. 1147, 1185 n.235 (1997) ("Only 18% of 
state and federal prisons offer experimental drugs and only 12% allow inmates access to clinical 
trials of drugs."). 
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Protection clauses. Because many clinical trials involve potential cures for 
diseases that frequently affect prison populations, such as hepatitis, 13 HIV 
infection, and tuberculosis, 14 regulations that are excessively stringent may 
deprive prisoners of life-saving therapy. 15 Currently, 1.8 million people are in 
jail in the United States at any given time. 16 Therefore, polices that bar prisoner 
participation in biomedical research adversely affect a very large number of 
Americans. 
This Article will analyze the constitutional issues implicated in biomedical 
research involving prisoners. It will argue that, in light of contemporary 
regulatory safeguards, the constitutional rights of prisoners enrolled in clinical 
studies will not be jeopardized. Moreover, the Article will encourage the 
inclusion of prisoner subjects in biomedical research involving potentially 
beneficial experimental treatment for life-threatening diseases and will assert that 
regulations banning the inclusion of prisoners in clinical studies are 
constitutionally suspect. This Article begins with an overview of clinical trials 
and informed consent. Next, a brief history ofthe abuses suffered by prisoners 
in clinical trials will be presented. The Article will then discuss the Nuremberg 
Code and the federal regulations applicable to research involving inmates. The 
constitutional issues relating to prisoners' participation in or exclusion from 
clinical trials will be analyzed at length. Finally, the author will address the 
practical and ethical difficulties of conducting biomedical experimentation in 
which prisoners participate and will provide specific recommendations regarding 
these impediments. 
I. CLINICAL TRIALS AND INFORMED CONSENT 
Clinical trials for drugs and devices are regulated by the Food and Drug 
Administration (FDA). 17 Clinical trials for procedures such as surgeries or bone 
marrow transplants are not regulated by the FDA but often must comply with 
DHHS regulations. 18 Drugs studied in clinical trials are called Investigational 
New Drugs ("INDs"). 19 Sponsors wishing to conduct a clinical trial to test a new 
13. See 45 C.F.R. § 46.306(a)(2)(iii). 
14. See Schar, supra note 12, at 1156. 
15. See id. at 1184-85. 
16. See Walter Shapiro, 1.8M Reasons for Criminal-Justice Reform, USA TODAY, Mar. 17, 
1999, at 2A. 
17. See 21 C.F.R. § 7.3(f) (1999) ("Product means an article subject to the jurisdiction of 
the Food and Drug Administration, including any food, drug, and device intended for human or 
animal use .... "). 
18. See 45 C.F.R. § 46.101 (applicable to any research that is conducted, funded, or 
regulated by any federal department or agency); Richard S. Saver, Note, Reimbursing New 
Technologies: Why Are the Courts Judging Experimental Medicine?, 44 STAN. L. REv. 1095, 
1110-11, 1122 (1992). 
19. See 21 C.F.R. § 312.23(a). 
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drug must submit an IND application to the FDA.20 In some circumstances, a 
drug still under investigation may be used to treat patients not participating in a 
clinical trial.21 Specifically, an IND may be used in treatment of patients if the 
drug is intended to treat a serious or immediately life-threatening disease, 22 and 
there is no comparable or satisfactory alternative drug ortherapy.23 The drug can 
be utilized in treatment if it is currently under investigation in a clinical trial, or 
if clinical trials have been completed and the sponsor is actively pursuing 
marketing approval with due diligence. 24 
Medical research for drugs and other treatments is conducted in three or four 
phases of clinical trials.25 In Phase I, the new drug is given to patients or healthy 
individuals to determine its toxicity, most effective method of administration, and 
safe dosage range.26 Participants in the trial receive increasing dosages of the 
substance in order to determine its metabolism, absorption, and side effects and 
to gain early evidence of its effectiveness, if possible.27 Phase I clinical trials 
generally involve only twenty to eighty subjects, last about a year, and have a 
very high failure rate.28 Seventy percent of drugs submitted for Phase I clinical 
trials fail to progress to Phase II.29 
Phase II trials are designed to determine the effectiveness of the therapy.30 
The treatment is administered to patients afflicted with the disease for which the 
therapy is intended, and the trial often involves 100 to 300 people and lasts about 
two years. 31 Approximately thirty-three percent of drugs submitted for clinical 
trials fail in Phase II testing.32 
Phase III clinical trials are conducted only after the treatment has proven 
effective through Phase I and II trials. 33 The third phase attempts to assess the 
medical results of the experimental therapy in comparison with standard therapy 
or no therapy at all.34 Phase III studies usually involve 1000 to 3000 patients and 
last about three years. 35 
20. See id. 
21. See id. § 312.34(a). 
22. See id. § 312.34(b)(I). 
23. See id. § 31.234(b)(ii). 
24. See id. § 312.34(b)(iv). 
25. See id. § 312.21(a)-(c); see also Veronica Henry, Problems with Pharmaceutical 
Regulation in the United States, 14 J. LEGAL MED. 617, 621 ( 1993 ). 
26. See 21 C.F.R. § 312.21(a) (1999); see also Henry, supra note 25, at 621. 
27. See 21 C.F.R. § 312.21(a); Henry, supra note 25, at 621. 
28. See 21 C.F.R. § 312.21(a); Henry, supra note 25, at 621. 
29. See Henry, supra note 25, at 621. 
30. See 21 C.F.R. § 312.21(b). 
31. See Henry, supra note 25, at 621. 
32. See id. 
33. See id.; see also 21 C.F.R. § 312.21. 
34. See Henry, supra note 25, at 621; 21 C.F.R. § 312.21 (1999). 
35. See Henry, supra note 25, at 621. 
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The FDA may also require postmarketing or Phase IV clinical trials.36 These 
studies are designed to determine the existence of less common adverse 
reactions, the effect of the drug on morbidity or mortality, and the effect of the 
drug on a particular patient population, such as children.37 
Research that is conducted, supported, or regulated by any federal 
department or agency must be reviewed by an Institutional Review Board 
("IRB").38 An IRB is a committee designated by an institution to review, 
approve, and periodically monitor biomedical research studies.39 The IRB 
receives a document known as the "protocol" regarding each clinical trial, which 
describes eligibility requirements for participants, the number of subjects to be 
tested, and the objective of the research.40 Each participant must sign an 
"informed consent" document through which he or she is fully informed of the 
details of the clinical trial.41 
Both IRBs and the contents of informed consent forms are extensively 
regulated by the Department of Health and Human Services. Each IRB must 
have at least five members with varying backgrounds and diversity in terms of 
race, gender, and culture.42 Each IRB must include at least one member whose 
principal concerns are in the scientific realm and one individual whose primary 
concerns are nonscientific (e.g. a lawyer or minister).43 Furthermore, each IRB 
must include at least one member who is not otherwise affiliated with the entity 
and who has no immediate family member affiliated with the institution.44 
Unless an expedited review is necessary, research protocols must be 
reviewed at meetings at which a majority of the members of the IRB are present, 
including at least one member whose professional expertise is nonscientific.45 
A majority of the members present must vote for the approval of the research 
before the medical investigator is permitted to proceed.46 
An IRB has authority to approve or disapprove the research activities it 
reviews or to require that they be modified.47 The IRB must provide written 
notification of its decisions to those who proposed the research and must conduct 
continuing reviews of research it approved at least yearly, or more often if the 
risks entailed necessitate a more frequent assessment.48 
In order to approve proposed research, an IRB must ensure that specific 
36. See 21 C.F.R. § 312.85. 
37. See id.; see also Henry, supra note 25, at 622. 
38. See 45 C.F.R. §§ 46.101(a); 46.103 (1998). 
39. See 21 C.F.R. § 56.102(g); 45 C.F.R. § 46.102(g) (1998). 
40. See 21 C.F.R. § 56.115; 45 C.F.R. § 46.115. 
41. See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116. 
42. See 21 C.F.R. § 56.107(a); 45 C.F.R. § 46.l07(a). 
43. See 21 C.F.R. § 56.107(c); 45 C.F.R. § 46.107(c). 
44. See 21 C.F.R. § 56.107(d); 45 C.F.R. §§ 46.107(d). 
45. See 21 C.F.R. § 56.108(c); 45 C.F.R. § 46.108(b). 
46. See 21 C.F.R. § 56.1 08( c); 45 C.F.R. § 46.1 08(b ). 
47. See 21 C.F.R. § 56.109(a); 45 C.F.R. § 46.109(a). 
48. See 21 C.F.R. § 56.1 09(e), (f); 45 C.F.R. § 46.109(d), (e). 
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criteria are met. These include: ( 1) risks to participants are minimized; (2) risks 
to subjects are reasonable in light of anticipated benefits; and (3) selection of 
participants is equitable, and the protocol is sensitive to the particularized 
problems of research involving vulnerable populations, such as children, 
prisoners, pregnant women, mentally disabled individuals, or economically or 
educationally deprived persons.49 
The information provided to participants on the informed consent document 
must be written in language that is comprehensible to the subject. 50 Informed 
consent may not include language that waives or appears to waive any of the 
subject's rights or releases the institution or personnel involved in the research 
from liability for negligence.51 The regulations further require that informed 
consent be obtained in writing from each participant, though certain exceptions 
are allowed.52 
The regulations detail the data that must be featured on the informed consent 
documentation. This information includes a description of the research, an 
explanation of its risks, benefits, and alternatives, a discussion of confidentiality, 
a list of contact people, and a statement that participation is voluntary and may 
be discontinued at any time. 53 
49. See 21 C.F.R. § 56.111 (a); 45 C.F.R. § 46.111 (a). 
50. See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116. 
51. See 21 C.F.R. § 50.20; 45 C.F.R. § 46.116. 
52. See 21 C.F.R. § 50.27; 45 C.F.R. § 46.117. 
53. See 21 C.F.R. § 50.25(a), (b); 45 C.F.R. § 46.116(a), (b). The provision reads in part 
as follows: 
{a) Basic elements of informed consent. ... in seeking informed consent the following 
information shall be provided to each subject: 
(1) A statement that the study involves research, an explanation of the purposes 
of the research and the expected duration of the subject's participation, a 
description of the procedures to be followed, and identification of any 
procedures which are experimental; 
{2) A description of any reasonably foreseeable risks or discomforts to the 
subject; 
(3) A description of any benefits to the subject or to others which may 
reasonably be expected from the research; 
( 4) A disclosure of appropriate alternative procedures or courses of treatment, 
if any, that might be advantageous to the subject; 
(5) A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained; 
(6) For research involving more than minimal risk, an explanation as to whether 
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While extensive federal regulations protect contemporary research subjects 
in the United States, regulatory safeguards are a relatively recent phenomenon. 54 
Absent governmentally-mandated constraints, medical researchers often abused 
and even tortured those involved in clinical trials, particularly when the 
participants were prisoners. The history of medical experimentation on prisoners 
both in this country and abroad is grim and sobering. 
any compensation and an explanation as to whether any medical treatments 
are available if injury occurs and, if so, what they consist of, or where further 
information may be obtained; 
(7) An explanation of whom to contact for answers to pertinent questions about 
the research and research subjects' rights, and whom to contact in the event 
of a research-related injury to the subject; and 
(8) A statement that participation is voluntary, refusal to participate will involve 
no penalty or loss of benefits to which the subject is otherwise entitled, and 
the subject may discontinue participation at any time without penalty or loss 
of benefits to which the subject is otherwise entitled. 
(b) Additional elements of informed consent. When appropriate, one or more of 
the following elements of information shall also be provided to each subject: 
(I) A statement that the particular treatment or procedure may involve risks to 
the subject (or to the embryo or fetus, if the subject is or may become 
pregnant) which are currently unforseeable; 
(2) Anticipated circumstances under which the subject's participation may be 
terminated by the investigator without regard to the subject's consent; 
(3) Any additional costs to the subject that may result from participation in the 
research; 
(4) The consequences of a subject's decision to withdraw from the research and 
procedures for orderly termination of participation by the subject; 
(5) A statement that significant new findings developed during the course of the 
research which may relate to the subject's willingness to continue 
participation will be provided to the subject; and 
(6) The approximate number of subjects involved in the study. 
45 C.F.R. § 46.116(a)-(b) (1998). 
54. The relevant federal regulations were promulgated only in the 1970s, as discussed in Part 
III below. 
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II. THE ABUSE OF PRISONERS IN CLINICAL TRIALS 
Throughout history many different cultures used prisoners for biomedical 
experimentation. In ancient Persia physicians were permitted to utilize 
incarcerated individuals as research subjects.55 The Roman empire subjected 
prisoners to the testing of poisons.56 Eighteenth century European physicians 
exposed prisoners to venereal disease, cancers, typhoid, and scarlet fever in order 
to conduct medical research.57 
In the United States the earliest known experimentation involving prisoners 
dates back to 1914, when white male convicts in Mississippi were used in 
pellagra studies. 58 Pellagra is a disease that causes dermatitis, diarrhea, dementia, 
and, at times, death. 59 The purpose of the experiment was to induce pellagra in 
twelve volunteers and to study the effects of diet on the disease.60 All twelve 
received pardons and survived, but they were not permitted to leave the clinical 
trial, even after suffering severe symptoms and begging to be released from it. 61 
In California, between 1919 and 1922, hundreds of prisoners took part in a 
testicular transplant experiment, designed to test whether lost male potency could 
be reinvigorated. 62 During World War II great enthusiasm developed for prisoner 
experimentation, and prisoners signed up for research trials in large numbers in 
order to show their patriotism.63 In New York scores of inmates volunteered for 
daily doses of various drugs to assist the Anny in determining whether soldiers 
could carry full workloads under the drugs' influence. 64 New Jersey supplied the 
Army with willing participants for research regarding sleeping sickness, sand-fly 
fever, and dengue fever. 65 In the Stateville Penitentiary in Illinois, more than 400 
prisoners were included in a two-year-long study aimed at finding a cure for 
malaria, and at the U.S. Penitentiary in Atlanta 600 inmates participated in other 
malaria research.66 As these experiments were developed, researchers began 
utilizing informed consent forms to provide test subjects with information 
regarding the trials so that investigators could claim that participants understood 
the studies in which they enrolled and so that authorities could be absolved from 
legal repercussions.67 A considerable portion of participants in the malaria 
55. See ENCYCLOPEDIA OF BIOETHICS, supra note I, at 2056. 
56. See id. 
57. See id. 
58. See id. 
59. See HORNBLUM, supra note 5, at 77. 
60. See id. at 78. 
61. See id. at 78-79. 
62. See id. at 79. 
63. See ENCYCLOPEDIA OF BIOETHICS, supra note I, at 2056. 
64. See HORNBLUM, supra note 5, at 81. 
65. See id. 
66. See id. at 81, 83. 
67. See id. at 82. 
2000] PRISONER PARTICIPATION IN CLINICAL TRIALS 483 
studies received pardons as a reward for their bravery.68 
The most notorious large-scale medical experimentation in human history 
was conducted by the Nazis during World War II. The elite of the German 
medical community subjected innocent victims in concentration camps to "a 
broad range of 'ghastly' and 'hideous"' experimentation.69 In Buchenwald and 
Natzweiler, numerous healthy inmates were involuntarily infected with yellow 
fever, smallpox, typhus, cholera, and diphtheria germs that caused hundreds of 
them to die. 70 In other camps Nazi doctors conducted experiments relating to 
high altitude, malaria, freezing, mustard gas, bone transplantation, sea water, 
sterilization, and incendiary bombs.71 
The full extent and inhumanity of the medical experimentation conducted by 
Nazi doctors in concentration camps became public knowledge during the 
Nuremberg Trials after World War 11.72 The Nuremberg Trials were opened on 
November 20, 1945 at the Palace of Justice in Nuremberg, Germany.73 Twenty 
three Nazi physicians were found guilty of "war crimes and crimes against 
humanity," and seven of them were sentenced to death. 74 At the trials the defense 
argued that the Nazis' research was no worse than "the wartime experiments in 
the United States such as those carried out at the Joilet, Illinois, prison in which 
treatments for malaria were sought by physicians who had to first infect the 
volunteer prisoners with the disease."75 These arguments failed, however, 
because the prosecution focused on the fact that in the concentration camps 
inmates had no choice regarding the torments to which they were subjected, and 
in the United States prisoners volunteered to participate in clinical trials. 76 
Japanese researchers also conducted barbarous experiments on prisoners in 
Manchuria during World War 11.77 The Japanese investigators, however, were 
never tried, and their crimes remained hidden from public scrutiny for over 
thirty-five years. 78 In exchange for silence, the Japanese agreed to share with the 
American government the data they had gathered regarding biological warfare 
through experimentation with Chinese captives.79 
As a result of the Nuremberg Trials, the Nuremberg Code was 
68. See id. 
69. !d. at 75. 
70. See id. 
71. See id. at 75, 77. 
72. See Colleen M. McCarthy, Note, Experimentation on Prisoners: The Inadequacy of 
Voluntary Consent, 15 NEW ENG. J. ON CR!M. & C!V. CONFINEMENT 55, 57 (1989). 
73. See Bernard D. Meltzer, "War Crimes:" The Nuremberg Trial and the Tribuna/for the 
Former Yugoslavia, 30 VAL. L. REv. 895,896 (1996). 
74. See McCarthy, supra note 72, at 57 n.IO. 
75. !d. (citing A.M. Capron, Human Experimentation, in I BIOLAW § 10, at 229 (1986)). 
76. See id. 
77. See id. 
78. See id. 
79. See id. 
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promulgated.80 The Code is included in the Nuremberg Military Tribunal's 
decision in the case of United States v. Karl Brandt. 81 The Code features 
ten points that delineate the circumstances under which medical 
experimentation on human subjects is permissible.82 During the latter part 
80. See id. at 57. 
81. See 5 ENCYCLOPEDIA OF BIOETHICS, supra note I, app. at 2763. 
82. Nuremberg Code (1947). The full text of the Nuremberg Code is as follows: 
I. The voluntary consent of the human subject is absolutely essential. 
This means that the person involved should have legal capacity to give consent; 
should be so situated as to be able to exercise free power of choice, without the 
intervention of any element of force, fraud, deceit, duress, over-reaching, or 
other ulterior form of constraint or coercion; and should have sufficient 
knowledge and comprehension of the elements of the subject matter involved 
as to enable him to make an understanding and enlightened decision. This 
latter element requires that before the acceptance of an affirmative decision by 
the experimental subject there should be made known to him the nature, 
duration, and purpose of the experiment; the method and means by which it is 
to be conducted; all inconveniences and hazards reasonably to be expected; and 
the effects upon his health or person which may possibly come from his 
participation in the experiment. 
The duty and responsibility for ascertaining the quality of the consent rests 
upon each individual who initiates, directs or engages in the experiment. It is 
a personal duty and responsibility which may not be delegated to another with 
impunity. 
2. The experiment should be such as to yield fruitful results for the good of 
society, unprocurable by other methods or means of study, and not random and 
unnecessary in nature. 
3. The experiment should be so designed and based on the results of animal 
experimentation and a knowledge of the natural history of the disease or other 
problem under study that the anticipated results will justify the performance of 
the experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical 
and mental suffering and injury. 
5. No experiment should be conducted where there is an a priori reason to believe 
that death or disabling injury will occur; except, perhaps, in those experiments 
where the experimental physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the 
humanitarian importance of the problem to be solved by the experiment. 
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of the Twentieth Century, prisoners have rarely, if ever, been involved in 
clinical trials outside of the United States.83 
In the United States, however, medical research involving prisoners 
continued for several decades after World War II. In 1953 testing on federal 
prisoners included research regarding hepatitis, heart disease, intestinal 
protozoan parasites, athlete's foot, and the common cold.84 In the early 1950s 
nearly 100% of participants in Phase I clinical trials across the United States 
were prisoners, according to the former chief of clinical investigations for the 
FDA, Dr. Alan B. Lisook.85 
The Ohio prison system was involved in some of the most dangerous and 
controversial experiments ofthe mid-1950s.86 The research was conducted in 
conjunction with the Sloan Kettering Institute for Cancer Research and Ohio 
State University's medical research department.87 Inmates volunteered to be 
injected with live cancer cells in both forearms. 88 Two weeks after the injection, 
the affected area of one forearm would be surgically removed for study, while the 
malignant cells remained in the other forearm for an indefinite period of time. 89 
Medical experimentation in the 1950s was not limited to physical ailments. 
At the Ionia State Hospital in Michigan, at least 142 inmates participated in 
secret mind-control experiments for the CIA. 90 The CIA gave numerous "sexual 
7. Proper preparations should be made and adequate facilities provided to protect 
the experimental subject against even remote possibilities of injury, disability, 
or death. 
8. The experiment should be conducted only by scientifically qualified persons. 
The highest degree of skill and care should be required through all stages of the 
experiment of those who conduct or engage in the experiment. 
9. During the course of the experiment the human subject should be at liberty to 
bring the experiment to an end if he has reached the physical or mental state 
where continuation of the experiment seems to him to be impossible. 
10. During the course of the experiment the scientist in charge must be prepared to 
terminate the experiment at any stage, if he has probable cause to believe, in the 
exercise ofthe good faith, superior skill and careful judgment required of him 
that a continuation of the experiment is likely to result in injury, disability, or 
death to the experimental subject. 
Id at 2763-64. 
83. See Schroeder, supra note 3, at 970; REPORT, supra note 2, at 3077. 
84. See HORNBLUM, supra note 5, at 89-90. 
85. See id. at 43. 
86. See id. at 93. 
87. See id. 
88. See id. 
89. See id. 
90. See id. at 95. 
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psychopaths" LSD and marijuana in order to "test the effectiveness of certain 
medication in causing individuals to release guarded information under 
interrogation. "91 
Biomedical experimentation on prisoners could be extremely lucrative for 
doctors. Dr. Austin R. Stough, an Oklahoma physician, is estimated to have 
earned approximately $1 million a year by selling blood plasma extracted from 
volunteer prisoners in Oklahoma, Arkansas, and Alabama and by using the 
prisoners for drug testing.92 His customers included Bristol-Myers, Merck, 
Sharp & Dohme, Upjohn, Lederle, and American Home Products.93 
Throughout the 1960s, in fact, drug companies competed for access to prison 
populations.94 In 1964, Upjohn and Parke-Davis contributed over a half million 
dollars to build a state of the art laboratory inside the State Prison of Southern 
Michigan at Jackson, which was the largest walled penitentiary in the world and 
housed 4100 inmates.95 Inmates were trained to run the tests in prison labs 
themselves and were paid between $.35 and $1.25 per day, a small fraction of 
what employees doing such work would earn in a non-prison environment.96 
Medical experimentation in prisons continued throughout the 1960s and early 
1970s.97 In 1969 eighty-five percent of all new drugs were tested on prisoners 
in forty-two prisons.98 As late as 1975 at least 3600 prisoners in the United 
States were used by drug companies as the first humans on whom the safety of 
new medication was tested.99 The federal government, through the Atomic 
Energy Commission, funded a decade-long radiation study on inmates in Oregon 
and Washington State prisons. 100 The experiments were designed to determine 
how much radiation U.S. astronauts could tolerate during space flights. 101 
Prisoners volunteered for the testing and received small monetary payments, but 
were required to undergo radiation exposure to their testicles at rates equivalent 
to approximately twenty diagnostic x-rays. 102 Test subjects suffered painful, 
lasting effects, and, according to some estimates, almost half of them have since 
died. 103 From 1970 to 1975 five agencies of the federal government utilized 
prison inmates in 125 biomedical experiments and nineteen behavioral research 
studies. 104 
91. !d. 
92. See id. at 97. 
93. See id. 
94. See id. at l03. 
95. See id. 
96. See id. 
97. See id. at 108. 
98. See Schroeder, supra note 3, at 971. 
99. See ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056-57. 
100. See HORNBLUM, supra note 5, at 107. 
101. See id. 
102. See id. 
103. See id. at 108. 
104. See ENCYCLOPEDIA OF BIOETHICS, supra note 1, at 2056. 
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In Petersburg, Virginia, Dr. John L. Sever of the National Institutes ofHealth 
conducted a rubella project, exposing prisoners to the disease for sixteen weeks 
at a time. 105 Inmates earned twenty dollars for their participation. 106 In California 
and Arizona prisoners were involved in weightlessness experiments for the 
National Aeronautic and Space Administration. 107 Prisoners were required to 
remain in bed at all times, some for over six months. 108 In addition, some were 
placed in compression suits and were forced to endure repeated blood and 
calcium tests and radioactive isotope injections. 109 Subjects were paid fifty 
dollars per month and an additional fifty dollars for completing the study.110 
They also signed informed consent forms, and these, unlike their predecessors, 
provided inmates with some degree of protection by stating that the consent 
forms "shall not be construed as a release ofNASA from any future liability."111 
In Acres of Skin, Allen M. Horn blum wrote an expose of the twenty-year 
testing program at Philadelphia's Holmesburg Prison. The program was run by 
Dr. Albert M. Kligman, a University of Pennsylvania dermatology professor. 112 
Hornblum is particularly critical of three biomedical experiments conducted 
by Kligman at the prison. First, in conjunction with the Army, he tested a mind-
altering substance known as EA 3167 on prisoners in an effort to determine 
whether it should be added to the Army's chemical warfare stock. 113 Inmates 
suffered confusion and hallucinations for up to three weeks. 114 In addition, 
Kligman tested radioactive isotopes at the prison despite having little education 
or experience in radioactive medicine. 115 Hornblum alleges that Kligman made 
various misrepresentations to the U.S. Atomic Energy Commission in order to 
obtain a required license from the federal government. 116 The third experiment 
denounced by Hornblum is one conducted for Dow Chemical Corporation, 
involving dioxin, a component of Agent Orange. 117 According to the book, 
Kligman subjected several prisoners to 7500 micrograms of the toxic substance, 
468 times the dosage he was instructed to administer by Dow Chemicals. 118 
Hornblum observes in his book that "[t]he Holmesburg experiments took 
place before the rise of investigative journalism, and the media, the government, 
I 05. See HORNBLUM, supra note 5, at I 08. 
106. See id. 
107. See id. 
108. See id. at 109. 
109. See id. 
110. Seeid.at108. 
111. /d. at 109. 
112. See id. at xix-xx, 35. Kligman is the inventor of Retin-A, the acne cream and wrinkle 
remover, which he tested on Holmesburg prisoners. See id. at 214. 
113. See id. at 127-30, 137, 141-43. 
114. See id. at 129. 
115. See id. at 14 9-61. 
116. See id. 
117. See id. at 163-83. 
118. See id. at 169. 
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and the public in general, neither knew nor cared about the events occurring daily 
within the walls ofthe old city jail."119 That indifference would vanish in the 
1970s. 
Ill. THE OUTCRY AGAINST EXPERIMENTATION ON PRISONERS 
AND ITS CONSEQUENCES 
Concern regarding the mistreatment of medical research subjects in the 
United States developed in the early 1970s, largely as a result of publicity 
concerning the Tuskegee syphilis study. 120 The Tuskegee study was conducted 
from the 1950s until the beginning of the 1970s and was designed to study the 
effects of untreated syphilis in a group of African American men. 121 The 
researchers professed to treat the patients, but never divulged to them that they 
were not being provided with the easily available and fully effective cure122 of 
penicillin. 123 The subjects thus continued to suffer from the debilitating illness 
while believing that they were receiving adequate care. 124 
The Senate held subcommittee hearings in 1973 and subsequently established 
the National Commission for the Protection of Human Subjects in Biomedical 
and Behavioral Research through the National Research Act of 197 4. 125 The 
National Commission operated between 1974 and 1978. 126 In 1976 the 
Commission recommended to the Secretary of the Department of Health, 
Education and Welfare ("HEW") (now "DHHS") that the government declare a 
moratorium on funding and approving prisoner studies until any prison that 
allowed inmate experimentation met at least minimum criteria to protect inmate 
subjects. 127 HEW published regulations for prisoner protection in clinical trials 
in 1978. 128 Although DHHS modified the regulations addressing biomedical 
research when it succeeded HEW, it retained the sections relating to prisoners. 129 
In general, DHHS regulations apply to any research involving human subjects 
that is conducted, supported, or regulated by any federal department or agency. 130 
DHHS regulations are designed to limit the circumstances in which 
researchers may include prisoners in their studies and to provide adequate 
119. /d. at 242. 
120. See McCarthy, supra note 72, at 58. 
121. See WILLIAM J. CURRAN ET AL., HEALTH CARE LAW AND ETHICS 276 (5th ed. 1998). 
122. See id. 
123. See THE BANTAM MEDICAL DICTIONARY 424 (rev. ed. 1990). 
124. See CURRAN ET AL., supra note 121, at 276. 
125. See Pub. L. 93-348, 88 Stat. 342, § 201; McCarthy, supra note 72, at 58-59. 
126. See BARUCH A. BRODY, ETHICAL ISSUES IN DRUG TESTING, APPROVALAND PRICING 103 
(1995). 
127. See ENCYCLOPEDIAOFBIOETHICS, supra note 1, at 2056; REPORT, supra note 2, at 3079-
81. 
128. See generally 45 C.F.R. § 46.301 (1998). 
129. See McCarthy, supra note 72, at 59. 
130. See 45 C.F.R. § 46.l01(a). 
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protection to inmate subjects. The regulations recognize that prisoners living in 
a harsh prison setting may be coerced into accepting risks that free citizens would 
not and that investigators may be tempted to utilize a "captive" group to undergo 
biomedical studies that would not be tolerated by civilians who are not 
incarcerated. 131 
The regulations impose special requirements and duties upon IRBs assessing 
clinical trials that involve prisoners. An IRB reviewing such research must 
include at least one prisoner or prisoner advocate, and a majority of its members 
may not be otherwise associated with the prison at issue. 132 
The IRB must ensure that the advantages that the prisoners enjoy through 
participation in the trial with respect to living conditions, healthcare, food, 
amenities, and potential earnings are not so great as to render the inmate unable 
to weigh the risks ofthe study against its benefits in the prison environment.133 
131. See Eileen Kelly, Expanding Prisoners' Access to AIDS-Related Clinical Trials: An 
Ethical and Clinical Imperative, 75 THE PRISON JOURNAL 48, 57 (1995). 
/d. 
132. See 45 C.F.R. § 46.304. The provision reads in relevant part as follows: 
In addition to satisfying the requirements in § 46.107 of this part, an Institutional 
Review Board, carrying out responsibilities under this part with respect to research 
covered by this subpart, shall also meet the following specific requirements: 
(a) A majority of the Board (exclusive of prisoner members) shall have no 
association with the prison(s) involved, apart from their membership on the 
Board. 
(b) At least one member of the Board shall be a prisoner, or a prisoner 
representative with appropriate background and experience to serve in that 
capacity, except that where a particular research project is reviewed by more 
than one Board only one Board need satisfy this requirement. 
133. See id. § 46.305(a)(2). The regulation found at 45 C.F.R. § 46.305(a) reads as follows: 
(a) In addition to all other responsibilities prescribed for Institutional Review 
Boards under this part, the Board shall review research covered by this subpart 
and approve such research only if it finds that: 
( 1) The research under review represents one of the categories of research 
permissible under§ 46.306(a)(2) [see infra note 139]; 
(2) Any possible advantages accruing to the prisoner through his or her 
participation in the research, when compared to the general living 
conditions, medical care, quality of food, amenities and opportunity for 
earnings in the prison, are not of such a magnitude that his or her ability to 
weigh the risks of the research against the value of such advantages in the 
limited choice environment of the prison is impaired; 
(3) The risks involved in the research are commensurate with risks that would 
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In addition, the risks involved in the trial must be equivalent to those that would 
be acceptable to non-inmate volunteers, 134 and the procedures implemented for 
the selection of participants should be fair and not subject to arbitrary 
intervention by prison officials or prisoners. 135 Information provided to prisoners 
for purposes of informed consent must be articulated in language that is 
comprehensible to the inmate population. 136 In addition, Parole boards may not 
consider prisoner participation in clinical trials when making parole decisions, 
and prisoners must be informed of this fact. 137 Finally, adequate follow-up care 
must be provided, when appropriate, to participants.138 
The regulations limit inmate participation in clinical investigations to the 
following: ( 1) studies of the possible causes, effects, and processes of 
imprisonment and criminal behavior so long as the research involves only 
minimal risk and inconvenience to the subject; (2) studies of prisons as 
institutional entities or of inmates as incarcerated individuals so long as the 
research involves only minimal risk and inconvenience to the subject; (3) 
research on particular conditions affecting prisoners as a class so long as the 
study is approved by the Secretary; and ( 4) research involving a treatment likely 
/d. 
be accepted by nonprisoner volunteers; 
(4) Procedures for the selection of subjects within the prison are fair to all 
prisoners and immune from arbitrary intervention by prison authorities or 
prisoners. Unless the principal investigator provides to the Board 
justification in writing for following some other procedures, control subjects 
must be selected randomly from the group of available prisoners who meet 
the characteristics needed for that particular research project; 
(5) The information is presented in language which is understandable to the 
subject population; 
(6) Adequate assurance exists that parole boards wiii not take into account a 
prisoner's participation in the research in making decisions regarding parole, 
and each prisoner is clearly informed in advance that participation in the 
research will have no effect on his or her parole; and 
(7) Where the Board finds there may be a need for follow-up examination or 
care of participants after the end of their participation, adequate provision 
has been made for such examination or care, taking into account the varying 
lengths of individual prisoners' sentences, and for informing participants of 
this fact. 
134. See id. § 46.305(a)(3). 
135. See id. § 46.305(a)(4). 
136. See id. § 46.305(a)(5). 
137. See id. § 46.305(a)(6). 
138. See id § 46.305(a}(7). 
2000] PRISONER PARTICIPATION IN CLINICAL TRIALS 491 
to benefit the prisoners themselves. 139 If a prisoner might be assigned to a 
placebo control arm, the study can proceed only with the Secretary's approval. 140 
The FDA, an agency ofDHHS, 141 published its own proposed regulations in 
1980.142 The regulations were substantially the same as those issued by 
I d. 
139. See id. § 46.306(a)(2). The regulation reads in relevant part: 
(a) Biomedical or behavioral research conducted or supported by DHHS may 
involve prisoners as subjects only if: 
(I) The institution responsible for the conduct of the research has certified to the 
Secretary that the Institutional Review Board has approved the research 
under§ 46.305 of this subpart; and 
(2) In the judgment of the Secretary [Health and Human Services] the proposed 
research involves solely the following: 
(i) Study of the possible causes, effects, and processes of incarceration, 
and of criminal behavior, provided that the study presents no more 
than minimal risk and no more than inconvenience to the subjects; 
(ii) Study of prisons as institutional structures or of prisoners as 
incarcerated persons, provided that the study presents no more than 
minimal risk and no more than inconvenience to the subjects; 
(iii) Research on conditions particularly affecting prisoners as a class (for 
example, vaccine trials and other research on hepatitis which is much 
more prevalent in prisons than elsewhere; and research on social and 
psychological problems such as alcoholism, drug addiction and sexual 
assaults) provided that the study may proceed only after the Secretary 
has consulted with appropriate experts including experts in penology 
medicine and ethics, and published notice, in the Federal Register, of 
his intent to approve such research; or 
(iv) Research on practices, both innovative and accepted, which have the 
intent and reasonable probability of improving the health or well-being 
of the subject. In cases in which those studies require the assignment 
of prisoners in a manner consistent with protocols approved by the 
IRB to control groups which may not benefit from the research, the 
study may proceed only after the Secretary has consulted with 
appropriate experts, including experts in penology medicine and ethics, 
and published notice, in the Federal Register, of his intent to approve 
such research. 
140. See id. § 46.306(a)(2)(iv). 
141. See Kelly, supra note 131, at 57. 
142. See Schroeder, supra note 3, at 984-85. 
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DHHS. 143 Nevertheless, on July 29, 1980 inmates in the Michigan State 
Penitentiary at Jackson filed a lawsuit challenging the proposed FDA 
regulations. 144 On November 12, 1980, the Upjohn Company, the primary 
sponsor of drug research at Jackson, intervened as a plaintiff in the case. 145 The 
plaintiffs alleged that the FDA's proposed ban on prisoner participation in 
nontherapeutic drug experimentation violated the Equal Protection and Due 
Process clauses of the Fifth Amendment. 146 With the lawsuit pending, the FDA 
stayed the effective date of its regulations. 147 The FDA has never removed its 
stay or reproposed its regulations. 148 
Existing federal regulations provide significant protection for prisoners 
participating in clinical trials. 149 Prisoner participation must be informed and 
voluntary and cannot pose more than minimal risk to the research subject. 
Despite the many safeguards implemented by DHHS, few inmates have access 
to clinical trials. 150 According to a survey conducted by the American 
Correctional Health Services Association, bioemedical research involving 
inmates is prohibited in twenty-two states. 151 Relatively few research institutions 
have accepted prisoners in clinical trials in recent years. These include facilities 
in Colorado, Connecticut, Maryland, New York, Texas, and Virginia. 152 
In light of history, a concern may exist that individuals cannot, under any 
circumstances, be adequately protected in a prison setting and that any 
biomedical experimentation will lead to a violation of the prisoners' legal and 
moral rights. While it is wise for researchers to be mindful of the sensitive 
143. See Kelly, supra note 131, at 59. 
144. See Fante v. Department of Health and Human Services, Civil Action No. 80-72778, 
(E.D. Mich. filed July 29, 1980), cited in 46 Fed. Reg. 35085 (1981). 
145. See id; Schroeder, supra note 3, at 986. 
146. See Fante, 46 Fed. Reg. at 35085; Schroeder, supra note 3, at 986. 
147. See Kelly, supra note 131, at 56. 
148. See id 
149. A recent statement issued by the Office of the Inspector General of the U.S. Department 
of Health and Human Services is highly critical of the institutional review board system. According 
to the report, the regulations are inadequately implemented and human subjects are insufficiently 
protected by IRBs. However, the report did not focus specifically on review of protocols involving 
prisoners, a process that is subject to higher standards. See OFFICE OF INSPECTOR GENERAL, U.S. 
DEP'T OF HEALTH & HUMAN SERVICES, INSTITUTIONAL REVIEW BOARDS: A TIME FOR REFORM 
( 1998); see also discussion infra Part V .B. Nevertheless, while the regulations themselves provide 
ample protection for prisoners, some IRBs may be inconsistent in applying the guidelines. The IRB 
system may therefore need to undergo scrutiny and improvement in order to ascertain that, in 
practice, prisoners consistently enjoy the benefits of the regulatory safeguards. 
150. See Schar, supra note 12, at 1185 n.235. 
151. See Kelly, supra note 131, at 58 (citing Kathryn Duke, Achieving Balance: Biomedical 
Research and Inmates, CORHEALTH, Falll993, at I, 2). 
152. See id. at 59. GARY L. STEIN & LINDA D. HEADLEY, NORTH JERSEY COMMUNITY 
RESEARCH INITIATIVE, PRISONERS WITH HIV: GUIDELINES FOR IMPLEMENTING CLINICAL TRIALS IN 
CORRECTIONAL SETTINGS 7 (July 1995). 
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circumstances of prisoners, it is also unwise to exclude inmates from all clinical 
trials. Denying seriously ill prisoners access to experimental treatments may 
constitute an equivalent violation of prisoner rights and is similarly problematic 
in moral and legal terms. The next section will focus on the potential 
constitutional issues implicated in biomedical experimentation involving 
prisoners. 
IV. ANALYSIS OF THE CONSTITUTIONAL RIGHTS OF PRISONERS AS THEY 
RELATE TO BIOMEDICAL EXPERIMENTATION 
A. While Irresponsible Clinical Research May Violate Prisoners ' 
Eighth Amendment Rights, Denial of Potentially Life-Saving 
Experimental Treatment to Prisoners Also Constitutes 
Unconstitutional Cruel and Unusual Punishment 
1. Eighth Amendment Overview.-The Eighth Amendment to the 
Constitution of the United States prohibits the infliction of "cruel and unusual 
punishment."153 The Supreme Court originally construed the Eighth Amendment 
as only precluding punishments oftorture and unnecessary cruelty154 or sentences 
that are grossly disproportionate to the crime committed. 155 The Supreme Court 
subsequently broadened its interpretation of the Eighth Amendment and 
determined that it applies to the treatment inmates receive while incarcerated, 156 
including improper medical treatment. 157 The Amendment is understood to 
embody "broad and idealistic concepts of dignity, civilized standards, humanity, 
and decency .... " 158 
Nevertheless, it is not easy for prisoners to prevail in Eighth Amendment 
cases. An inmate alleging an Eighth Amendment violation must establish a grave 
deprivation of rights to which prison officials have reacted with deliberate 
indifference. 159 In determining whether a punishment violates the Eighth 
153. U.S. CONST. amend. VIII. The text provides that "[e]xcessive bail shall not be required, 
nor excessive fines imposed, nor cruel and unusual punishment inflicted." !d. 
154. See Wilkerson v. Utah, 99 U.S. 130 (1878) (holding that death by firing squad is not 
cruel and unusual punishment). 
155. See Weems v. United States, 217 U.S. 349,382 (1910). In Weems the Court held that 
the Eighth Amendment's cruel and unusual punishment clause was "progressive, and is not fastened 
to the obsolete, but may acquire meaning as public opinion becomes enlightened by a humane 
justice." !d. at 378. See also Samantha A. Moppett, Case Comment, Constitutional 
Law-Extending Eighth Amendment Protections to Prisoners Involuntarily Exposed to 
Unreasonable Levels of Environmental Tobacco Smoke-Hel!ing v. McKinney, 28 SUFFOLK U. L. 
REv. 200,202 (1994). 
156. See Helling v. McKinney, 509 U.S. 25, 31 (1993); Moppett, supra note 155, at 202. 
157. See Estelle v. Gamble, 429 U.S. 97, 106 (1976). 
158. Jackson v. Bishop, 404 F.2d 571,579 (8th Cir. 1968)(summarizingthe Supreme Court's 
cases and concluding that the limits of the Eighth Amendment are "not easily or exactly defined"). 
159. See Gamble, 429 U.S. at I 06 ("In order to state a cognizable claim, a prisoner must 
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Amendment, the Supreme Court has assessed the challenged punitive measure 
in light of the "evolving standards of decency that mark the progress of a 
maturing society."16° Furthermore, the Court has found that deliberate 
indifference "entails something more than mere negligence ... [but] something 
less than acts or omissions for the very purpose of causing harm or with 
knowledge that harm will result."161 In order to establish a deliberate 
indifference claim based on improper medical treatment, an inmate must show 
that prison officials (1) were aware ofthe individual's serious medical need; and 
(2) disregarded, ignored, or refused to provide the inmate with treatment for that 
need. 162 
If an Eighth Amendment violation arises not from the acts of particular 
prison officials but from a prison policy, a different test, first articulated by the 
Supreme Court in 1987 in Turner v. Safley, 163 will be applied. In Safley, the 
Court held that "when a prison regulation impinges on inmates' constitutional 
rights, the regulation is valid if it is reasonably related to legitimate penological 
interests."164 In assessing the reasonableness of a regulation, the court must 
consider the following four factors: 
(1) 'there must be a "valid, rational connection" between the prison 
regulation and the legitimate governmental interest put forward to justify 
it;' (2) the court should determine whether there are alternative means 
of exercising the constitutional right that remain open to the inmates; (3) 
the court is to consider the impact that accommodation of the asserted 
constitutional right will have on guards, other inmates, and on the 
allocation of prison resources; and (4) the court should assess whether 
there are ready alternatives to the prison regulation-the absence of such 
ready alternatives suggests that the regulation is reasonable while their 
existence may be evidence of the opposite. 165 
2. Bailey v. Lally.-The case of Bailey v. Lally166 provides a uniquely 
thorough analysis of an Eighth Amendment challenge to the inclusion of prison 
inmates in clinical trials. In Bailey, state prisoners brought a class action under 
42 U .S.C. § 1983 alleging that prisoners who participated in clinical 
investigations at the Maryland House of Correction's medical research unit had 
allege acts or omissions sufficiently harmful to evidence deliberate indifference to serious medical 
needs."). 
160. Trop v. Dulles, 356 U.S. 86, 101 (1958). 
161. Farmer v. Brennan, 511 U.S. 825, 835 (1994). 
162. See id. at 837. 
163. 482 U.S. 78 (1987). In Safley inmates challenged two regulations promulgated by the 
Missouri Division of Corrections. The Court upheld the regulation concerning inmate-to-inmate 
correspondence but found the inmate marriage regulation to be invalid. 
164. !d. at 89. See also Lewis v. Casey, 518 U.S. 343, 361 (1996). 
165. Walker v. Sumner, 917 F.2d 382, 385 (9th Cir. 1990)(quoting Safley, 482 U.S. at 90-
91). 
166. 481 F. Supp. 203 (D. Md. 1979). 
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suffered violations of their constitutional rights to due process, privacy, and 
protection against cruel and unusual punishment.167 After careful consideration 
and lengthy discussion, the court ruled against the plaintiffs. 
A recitation of the facts is important to understanding the court's analysis 
and thus, will be provided in some detail. The Maryland House of Correction 
("MHC") was opened in 1879 and was designed to house approximately 1100 
inmates. 168 During the early 1970s the inmate population ranged from 1498 to 
1617, and many cells designed for only one person housed two occupants at a 
time. 169 Until1976, hot water was unavailable to prisoners. 170 During the winter, 
inmates suffered from the cold because the prison's heating system was sorely 
inadequate, and in the summer months, the facility was very hot. 171 A large 
percentage of prisoners had no work, educational, or vocational activities and 
spent between sixteen and seventeen hours per day in their cells. 172 Those with 
jobs earned between $.63 and $1.46 per day, with the vast majority earning under 
$1.1 0 a day. 173 
A medical research unit was established at the MHC by doctors from the 
University of Maryland School of Medicine, and research involving prisoners 
commenced in 1958.174 Prisoners participating in clinical trials were paid two 
dollars per day, including Saturdays and Sundays, and additional payments were 
made if the prisoner underwent particular medical procedures. 175 Approximately 
one third of the participants lived full-time in a designated section of the medical 
research unit that, unlike the rest of the prison, had hot water, color television, 
and three separate bathroom facilities. 176 The patients could retain their jobs and 
enjoy the income earned from the medical research as a supplement to other 
earnings. 177 Participation in clinical trials, however, had no impact on parole 
decisions. 178 This fact was disclosed to some, but not all of the inmates. 179 
Prisoners learned of the medical research unit via word of mouth or from an 
application that some were given when they entered MHC and that was also 
published in the prison newspaper. 180 Inmates wishing to be included in the 
medical experimentation were required to complete the application, which 
167. Seeid. 
168. See id. at 205. 
169. See id. 
170. See id. 
171. See id. 
172. See id. 
173. See id. at 205-06. Prisoners working in the laundry earned $2.22 per day. See id. 
174. See id. at 206. 
175. See id. 
176. See id. 
177. See id. 
178. See id. 
179. See id. at 209-10. 
180. See id. at 207. 
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included detailed information regarding the research. 181 When a study was to be 
commenced, all applicants would be gathered as a group and addressed by a 
nurse or a doctor, who explained the reason for and nature of the experimentation 
as well as its possible risks. Inmates who again expressed interest in participation 
underwent a physical examination and were given repetitive oral explanations in 
layman's terms, with opportunities for questions and answers. 182 
Those who were ultimately accepted as participants in the studies were given 
additional verbal data about the research and were told that they could withdraw 
at any time. 183 Many in fact did withdraw both before and during various stages 
of experimentation. 184 Prisoners were also asked to sign a written consent 
form.1s5 
The medical research unit at MHC conducted nontherapeutic studies of 
various infectious diseases including malaria, cholera, shigella, viral diarrhea, 
influenza, typhoid, e. coii, and rhinovirus. 186 Nontherapeutic studies are those 
that do not provide any direct medical benefit to the patient but seek to produce 
general knowledge about a particular disorder or condition. 187 All of the diseases 
investigated, with the exceptions of the common cold and the flu, had known 
cures. 188 Approximately fourteen percent of the prisoners incarcerated at MHC 
from 1971 to 197 5 participated in the medical studies. 189 
The plaintiffs alleged in their lawsuit that the poor prison conditions, their 
idleness, and the salary, which far exceeded earnings from other prison jobs, 
rendered their participation in the clinical trials coerced and consequently 
resulted in violations of their Eighth Amendment and other constitutional 
rights. 190 The Eighth Amendment claim revolved around the question of whether 
individuals incarcerated in a prison setting can give truly meaningful consent and 
rationally choose to volunteer for the trial with a full understanding of both its 
benefits and its risks. 191 
The Bailey court found that the prisoners were adequately informed in light 
of the numerous verbal explanations and the written consent forms they 
received. 192 The plaintiffs' strongest allegations were thus rooted in the issue of 
voluntariness. The plaintiffs argued that the overcrowded and extremely 
uncomfortable conditions of regular institutional life at MHC caused them to 
over-value the potential earnings and hours away from their cells and deprived 
181. See id. 
182. See id. at 208. 
183. See id. at 210. 
184. See id. 
185. See id. 
186. See id. at 212 n.15. 
187. See 45 C.F.R. § 46.406 (1998). 
188. See Bailey, 481 F. Supp. at 212. 
189. See id. at 220. 
190. See id. 
191. See id. at 219-20. 
192. See id. 
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them of the ability to make a meaningful decision. 193 
The court rejected the plaintiffs' claims. It noted that in fact a very small 
minority of prisoners (only fourteen percent) found the medical research 
programs appealing and that there was a constant shortage ofvolunteers. 194 In 
addition, the court noted the following: 
Prisoners at the MHC were not subject to physical abuse, or confined in 
segregated cells, or restricted to meagre [sic] diets, until they consented 
to participate in MRU studies. Prisoners were not pressured to 
participate. To the contrary, prisoners had a viable choice and, even 
after choosing to participate, had the option to withdraw from the 
medical studies. 195 
The court decision also emphasized that the experiments did not create a danger 
to the subjects' lives or future health and that the risks of temporary discomfort 
were fully disclosed to the inmates. 196 Finally, the court focused upon the fact 
that participation in the clinical studies did not facilitate the inmates' release 
from MHC, and thus, early parole was not an incentive for enrollment. 197 The 
court found that the plaintiffs' Eighth Amendment claim failed because the 
defendant's conduct was not "incompatible with evolving standards of 
decency" 198 and did not subject them to undue coercion. 199 
The medical research in the Bailey case was conducted before the DHHS 
issued its regulations for prisoner research in 1978.200 Today prisoners involved 
in clinical trials would enjoy far greater protection than that available to the 
plaintiffs in the Bailey case.201 Moreover, the experimentation conducted in 
Bailey, which was found not to violate any constitutional rights, would be 
prohibited by DHHS regulations because it was nontherapeutic, did not benefit 
the subjects, and did not fall into any ofthe categories of permissible research.202 
In light of contemporary regulatory safeguards and the restrictions placed on 
investigators conducting research involving prisoners, it is extremely unlikely 
that prisoner participants would suffer a violation of Eighth Amendment rights 
in the context of a clinical trial that complies with federal guidelines. 
3. Seriously Ill Prisoners May Greatly Benefit from Experimental 
Therapies .-In many instances, experimental treatments provided through 
clinical trials constitute last chance therapies for desperately ill patients who 
193. See id. at 220. 
194. See id. 
195. !d. 
196. See id. at 221. 
197. See id. 
198. /d. at219. 
199. See id. at 221. 
200. See McCarthy, supra note 72, at 59. 
201. See discussion supra Part III. 
202. See 45 C.F.R. § 46.306(a)(2) (1998). 
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cannot be cured by conventional medicine.203 In the prison setting, where a 
significant percentage of inmates are mv positive, experimental treatments 
could benefit many individuals and save many lives.204 Experimental treatments 
may also be sought by inmates suffering from cancer/05 hepatitis,206 
tuberculosis,207 and other diseases. 
HIV is one of the predominant health problems in U.S. prisons. 208 While 
HIV had an incidence rate of eighteen cases per 100,000 in the general 
population in 1992, the rate among prisoners was estimated to be 362 per 
100,000 that same year.209 Accounting for up to two-thirds of all inmate deaths 
in some states, AIDS is the leading killer in correctional facilities. 210 A 1992-93 
survey conducted by the National Institutes of Justice ("NIJ") and the federal 
Centers for Disease Control and Prevention ("CDC") revealed a total of more 
than 11,500 AIDS cases and almost 3500 AIDS-related deaths among prisoners 
in state, federal, county, and large city correctional facilities. 211 The New Jersey 
Department of Health estimates that almost nine percent of adult male inmates 
and more than fourteen percent of adult female inmates are infected with HIV. 212 
The Department further estimates that among prisoners with a history of illegal 
drug use, forty percent of the men and 42.6% of the women are HIV positive.213 
Inmates who are mv positive are highly susceptibletotuberculosis.214 From 
1976 to 1978, tuberculosis had an incidence rate of15.4 per 100,000 among New 
York state prisoners.215 By 1992 there was a 1300% increase to a rate of 189 per 
100,000.216 
Despite significant advances in the treatment of AIDS, contemporary 
treatment modalities offer only limited relief to patients.217 Participation in 
clinical trials can provide inmates with access to promising experimental 
drugs.218 At times, experimental protocols may constitute the only meaningful 
203. See Angela R. Holder, Funding Innovative Medical Treatment, 57 ALB. L. REv. 795, 
795 (1994). 
204. See Kelly, supra note 131, at 48. 
205. See Holder, supra note 203, at 795-96. 
206. See 45 C.F.R. § 46.306(a)(2)(iii). 
207. See Schar, supra note 12, at 1156. 
208. See James W. Marquart et al., Health Condition and Prisoners: A Review of Research 
and Emerging Areas of Inquiry, 77 THE PRISON JOURNAL 185 (1997). 
209. See id. 
210. See Kelly, supra note 131, at 49. 
211. See STEIN & HEADLEY, supra note 152, at 4. 
212. See id. 
213. See id. 
214. See Curtis Prout, Clinical Challenges in the Climate of Prison, 107 TRANSACTIONS OF 
THE AM. CLIMATOLOGICAL AND CLINICAL ASS 'N 287, 290 ( 1995). 
215. See id. 
216. See id. 
217. See STEIN & HEADLEY, supra note 152, at 4. 
218. See id. at 9. Since prisoners are precluded from participating in placebo-controlled 
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opportunity for a prisoner to receive treatment.219 Biomedical research may also 
provide inmates with the moral satisfaction of contributing to the advancement 
of AIDS research220 and with the opportunity "to give something back to society, 
to redeem, atone, and reconcile."221 Several commentators have urged the 
inclusion of prisoners in clinical trials relating to HIV and AIDS222 and in other 
studies that might benefit prisoners.223 
Regulations prohibiting seriously ill prisoners from participation in clinical 
trials in all cases, including those in which their exclusion results in the denial 
of potentially life-saving therapy, are vulnerable to constitutional attack. 
Although no court has rendered a decision regarding this issue, a viable 
constitutional argument can be made that prisoners with life-threatening illnesses 
that cannot be otherwise treated have a right to participate in biomedical research 
that complies with federal regulations.224 
4. The Eighth Amendment Right to Medical Treatment.-The Supreme Court 
has determined that the government is obligated to provide medical care for 
prisoners because incarcerated individuals cannot independently obtain 
healthcare. 225 The Court has further stated that "deliberate indifference to serious 
medical needs of prisoners constitutes the 'unnecessary and wanton infliction of 
pain,' proscribed by the Eighth Amendment."226 A prisoner may bring a cause 
of action for an Eighth Amendment violation under 42 U.S.C. § 1983 if 
studies unless the research is approved by the Secretary, prisoners will rarely be deprived of active 
therapy as research subjects. Generally, those assigned to the control arm of the study will be given 
standard therapy from which they are likely to benefit. 
219. See Dale L. Moore, An IRB Member's Perspective on Access to Innovative Therapy, 57 
ALB. L. REV. 559, 571-72 (1994) ("[A] significant component of the treatment available to AIDS 
patients is provided through clinical research trials of new drugs or drug combinations."). 
220. See STEIN & HEADLEY, supra note 152, at 9. 
221. Richard W. Garnett, Why Informed Consent? Human Experimentation and the Ethics 
of Autonomy, 36 CATH. LAW. 455,481 (1996). 
222. See, e.g, STEIN & HEADLEY, supra note 152, at 9; Kelly, supra note 131, at 55; Moore, 
supra note 219, at 571-72. 
223. See, e.g, Prout, supra note 214, at 291. Prout argues that "[t]here is a crying need for 
genetic studies" because significant evidence indicates that many prisoners have fathers and 
grandfathers who were also incarcerated. Id Prout admits, however, that this proposal is 
controversial because of"fears ofbreaches of confidentiality, manipulation of the data, and possible 
political implications having to do with race and ethnicity." /d. at 291-92. 
224. Several commentators have argued that the Eighth Amendment requires that sexual 
offenders who request castration as therapy for their paraphiliac disabilities be provided with the 
surgical treatment once proper medical evaluation and informed consent have been obtained. Their 
thesis features several parallels to the arguments made in this Article. See William Winslade et al., 
Castrating Pedophiles Convicted of Sex Offenses Against Children: New Treatment or Old 
Punishment?, 51 SMU L. REV. 349 (1998). 
225. See Estelle v. Gamble, 429 U.S. 97, 103 (1976). 
226. /d. at 104 (quoting Gregg v. Georgia, 428 U.S. 153, 171 (1976)). 
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authorities show deliberate indifference to his or her serious illness or injury.227 
In Helling v. McKinney28 a prisoner alleged that prison authorities had 
subjected him to cruel and unusual punishment by assigning him to a cell with 
an inmate who smoked five packs of cigarettes a day, and thus the officials had 
jeopardized his health. 229 The complaint further asserted that cigarettes were sold 
to inmates in the prison and that nonsmoking inmates were not informed of the 
health hazards associated with breathing smoke produced by their cellmates.230 
The Supreme Court held that the Eighth Amendment's protection against 
deliberate indifference to a prisoner's health problems extends not only to current 
serious health problems, but also to conditions that threaten to cause health 
problems in the future. 231 Consequently, the prisoner stated a cause of action 
under the Eighth Amendment when he alleged that prison officials had, with 
deliberate indifference, exposed him to levels of environmental tobacco smoke 
that created an unreasonable risk of serious damage to his health in the future. 232 
In order to obtain injunctive relief, however, the plaintiff would be required on 
remand to prove both an objective and a subjective element.233 First, he would 
have to prove that society considers the risk of which he complains "to be so 
grave that it violates contemporary standards of decency to expose anyone 
unwillingly to such a risk."234 Second, the inmate would be required to establish 
the subjective factor that prison officials had shown deliberate indifference to the 
hazards posed to his health.235 To do so, the plaintiff would need to focus upon 
the officials' current attitudes and conduct.236 
If exposure to environmental tobacco smoke can constitute an Eighth 
Amendment violation, it stands to reason that the denial of experimental therapy 
to an incarcerated person who is seriously ill could also rise to the level of a 
constitutional violation. If a clinical trial is available for a prisoner who suffers 
from AIDS or another serious illness and prison officials deny the inmate access 
to the trial, the inmate. might be able to establish a valid cause of action. The 
prisoner would have to show that failure to allow him access to the available 
clinical study is so grave that it violates contemporary standards of decency.237 
If the illness at issue is a terminal one, such as cancer or AIDS, for which 
conventional treatments have failed, this element may not be difficult to 
establish. In addition, the prisoner will have to prove that the prison officials had 
shown deliberate indifference to his medical condition by preventing him from 
227. See id. at 105. 
228. 509 u.s. 25 (1993). 
229. See id. at 28. 
230. See id. 
231. See id. at 33. 
232. See id. at 35. 
233. See id. at 36. 
234. !d. 
235. See id. 
236. See id. 
237. See id. 
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participating in the biomedical research.238 Success in establishing this element 
will depend upon the prison officials' reasoning and motivations.239 However, 
under Helling, the prisoner will not be required to prove that exclusion from the 
clinical trial posed an immediate risk of physical deterioration, but rather, only 
that his or her future health may be jeopardized.240 This principle is important 
for prisoners who are HIV positive since HIV patients may be asymptomatic or 
minimally symptomatic for many years. However, their future prognosis will 
depend upon the therapy that they receive throughout the course of the disease, 
and therapy for mv patients often includes experimental drug combinations.241 
If a state implements a regulation that prohibits prisoner participation in 
clinical trials, as many states have done, the Safley test would be used to evaluate 
any constitutional claim asserted by a prisoner.242 If the prisoner could establish 
that the regulation denying access to research studies impinges upon inmates' 
Eighth Amendment rights as discussed above, the prisoner would have to address 
the following issues: (1) whether a valid, rational connection exists between the 
prison regulation and the legitimate governmental interest that purportedly 
justifies it; (2) whether alternative means of exercising the constitutional right 
remain open to the prisoners; (3) the impact that accommodating the 
constitutional right will have on guards, other inmates, and prison resources; and 
(4) whether there are ready alternatives to the prison regulation.243 
Prisoners denied access to potentially life-saving experimental treatments 
because of a prison regulation should be able to establish all four elements. 
Under the Safley test, it is not enough for state officials merely to articulate a 
reason for their decision. Rather, the officials' reasoning is subjected to judicial 
scrutiny.244 The Safley test has served as a basis for invalidating prison policies 
in several cases. The case of Muhammad v. Pitcher/45 for example, involved a 
prison policy of treating inmate mail from the State Attorney General's Office 
as ordinary mail rather than legal mail and opening it while the addressee was not 
present.246 The court found that opening the mail in the absence of the prisoners 
burdened the inmates' First Amendment rights and was not reasonably related to 
legitimate penological interests.247 Contrary to the defendant's contentions, the 
court found that a requirement that mail from the Attorney General's Office be 
opened only in the presence of the addressee would not waste prison resources.248 
Moreover, treatment of mail from the Attorney General as ordinary mail left no 
238. See id. 
239. See id. 
240. See id. at 33. 
241. See Moore, supra note 219, at 571-72. 
242. See Turnerv. Safley, 482 U.S. 78,89 (1987). 
243. See id. at 89-90. 
244. See id. 
245. 35 F.3d 1081 (6th Cir. 1994). 
246. See id. 
247. See id. at 1085. 
248. See id. 
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alternative for prisoners who wished to communicate confidentially with the 
Attorney General in order to redress grievances.249 Similarly, in Castillo v. 
Gardner,250 the court found that a prison policy of conducting digital rectal 
probes without cause failed the Turner v. Safley test because it was not 
reasonably related to a legitimate penological goal.251 
In the case of a policy barring access to clinical research, the governmental 
entity promulgating the regulation would presumably assert that the reason for 
its regulation is the protection of prisoners against the abuses of biomedical 
experimentation. As discussed above, however, DHHS regulations implement 
multiple safeguards to protect prison populations.252 In light of these regulatory 
requirements and precautions, it will be difficult for prison authorities to justify 
complete denial of access to clinical trials as a reasonable antidote to prisoner 
abuse.253 
If promising treatment for a particular disease is available to the inmate only 
through an experimental study, as is often the case for AIDS patients/54 prisoners 
will have no alternative and no way to exercise their constitutional right to 
medical treatment outside of the clinical trial. In some cases, last-chance 
experimental therapies provided through clinical trials constitute the only 
meaningful healthcare available to a terminally ill patient. Prisoners seeking 
participation in such biomedical research will therefore be able to prevail with 
respect to the second element of the Safley test. 
The third element of the Safley test might provide the greatest hurdle for 
inmates challenging a prison regulation that prohibits access to clinical trials, but 
it should not be insurmountable. Prison officials might argue that 
accommodation of the prisoner's desire to participate in a study may have an 
adverse impact on guards, other inmates, and prison resources. The prison may 
contend that special treatment of some prisoners for medical research purposes 
might cause jealousy among inmates, require additional security measures for 
prisoners transported to and from the medical site, and result in added costs for 
the correctional facility. 
The inconvenience for correctional institutions allowing prisoner 
participation in clinical trials, however, should be minimal. Under FDA 
regulations, sponsors of drug studies are generally required to pay for the 
investigational drugs provided in trials.255 Consequently, the drug companies 
249. See id. 
250. 854 F. Supp. 725 (E.D. Wa. 1994). 
251. See id. at 726. 
252. See discussion supra Part III. 
253. The state might also argue that the regulation is necessary for security and cost reasons. 
Allowing an inmate to leave the prison in order to receive the experimental treatment could 
potentially raise expenses and security concerns for prison authorities. These arguments are 
addressed with respect to the third element of the Safley test below. 
254. See Kelly, supra note 131. 
255. See 21 C.F.R. § 312. 7(d)(l)(1999). "Charging for an investigational drug in a clinical 
trial under an IND is not permitted without the prior written approval of FDA. In requesting such 
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themselves pay for the treatment of prisoners who receive experimental therapy 
in clinical research.256 Moreover, during the 1960s, prior to the constraints 
imposed by federal regulations, drug companies competed for access to prisoner 
populations.257 Upjohn and Parke-Davis built a state of the art laboratory inside 
the State Prison of Southern Michigan at Jackson.258 If researchers were 
encouraged to utilize prisoners in clinical trials that would benefit both the 
sponsors and the prisoners, as required by the regulations, drug companies and 
research institutions may once again be eager to provide medical facilities within 
the prisons at which the studies would be conducted. In the past decade, 
researchers in Maryland and Colorado have in fact conducted AIDS-related 
clinical trials at correctional facilities. 259 At other locations, clinical studies have 
taken place at hospitals that provide routine medical services to prisoners and to 
which prisoners are transported for healthcare on a regular basis.260 
In addition, experience has shown that prisoners do not vie with one another 
for the opportunity to be research subjects and that there is often a dearth of 
inmates willing to participate in clinical research.261 Therefore, it is unlikely that 
the availability of experimental protocols for seriously ill inmates will be 
perceived as favoritism and cause morale problems within the prison. On the 
contrary, all prisoners might be reassured by the enhanced quality of the medical 
care and the new treatment opportunities available at the correctional facility. 
The cost and inconvenience for prison authorities would thus be slight. 
With respect to the fourth element of the Safley test, it should not be difficult 
to show that prison authorities wishing to protect prisoners from coerced or 
uninformed participation in clinical research or from abusive medical practices 
have ready alternatives to an absolute ban on access to clinical studies. Prison 
authorities could ensure that an appropriately constituted IRB has approved the 
proposed clinical study and that all other regulatory requirements are being 
followed by those conducting the research. In this manner, prison officials will 
be able to protect the prison population without denying seriously ill patients 
potentially life-saving therapy. 
approval, the sponsor shall provide a full written explanation of why charging is necessary in order 
for the sponsor to undertake or continue the clinical trial, e.g., why distribution of the drug to test 
subjects should not be considered part of the normal cost of doing business." !d. 
256. See id. Ifthe inmate receives standard therapy in a control arm, the drug sponsor does 
not have to cover the expense. However, this does not add costs for the state since the patient 
would have to be treated with standard therapy at the state's expense if no experimental therapy 
were available. 
257. See HORNBLUM, supra note 5, at 103. 
258. See id. 
259. See Kelly, supra note 131, at 61. 
260. See id. at 60. 
261. See Bailey v. Lally, 481 F. Supp. 203, 220 (D. Md. 1979); STEIN & HEADLEY, supra 
note 152, at 21 ("The [prison] population is not very anxious to participate."). 
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B. The Fourteenth Amendment Does Not Bar Prisoner Access to 
Experimental Treatment and May, in Fact, Mandate 
Inmates' Inclusion in Clinical Trials 
1. Due Process and Equal Protection.-The Fourteenth Amendment 
provides that no state may "deprive any person of life, liberty, or property, 
without due process of law; nor deny to any person within its jurisdiction the 
equal protection of the laws."262 The Supreme Court has stated that "[d]ue 
process of law is a summarized constitutional guarantee of respect for those 
personal immunities which ... are 'so rooted in the traditions and conscience of 
our people as to be ranked as fundamental' 263 •.• or are 'implicit in the concept 
of ordered liberty."'264 Traditionally, the Supreme Court has held that a state 
violates substantive due process when its acts "shock the conscience" of 
humanity.265 
Governmental action is subjected to strict scrutiny if it impermissibly 
interferes with the exercise of a fundamental right or disadvantages a suspect 
class. 266 If no fundamental right or particular suspect class is adversely affected, 
the challenged governmental action will be assessed under "rational basis 
scrutiny" to determine whether it bears a rational relationship to a legitimate 
governmental interest.267 The Supreme Court has determined that the 
fundamental rights protected by the Due Process Clause include the rights to 
marry, to marital privacy and contraception, to abortion, to have children, to 
control the education and upbringing of·one's children, to bodily integrity, and 
to refuse unwanted lifesaving medical treatment.268 The suspect classifications 
that warrant strict scrutiny under the Equal Protection Clause are race, alienage, 
and national origin.269 
The Bailey70 court held that the defendants' conduct did not rise to the level 
of a constitutional due process violation.271 The court acknowledged that some 
of the living conditions that were prevalent at MHC at the time were 
unacceptable and, that the research studies offered prisoners a partial escape from 
262. U.S. CONST. amend. XIV. 
263. Rochin v. California, 342 U.S. 165, 169 (1951) (citing Snyder v. Massachusetts, 291 
U.S. 97, I 05 (1934)). 
264. !d. (citing Palko v. Connecticut, 302 U.S. 319, 325 (1937)). 
265. See Bailey, 481 F. Supp. at 219 (citing Rochin, 342 U.S. at 172). 
266. See Massachusetts Bd. of Retirement v. Murgia, 427 U.S. 307, 312 (1976). 
267. See Harris v. McRae, 448 U.S. 297, 326 (1980). 
268. See Washington v. Glucksberg, 521 U.S. 702, 719-20 (1997). 
269. See Cleburne v. Cleburne Living Ctr., Inc., 473 U.S. 432, 440 (1985). An intermediate 
level of scrutiny has been applied in cases involving classification based on sex or illegitimacy. See 
Clark v. Jeter, 486 U.S. 456, 461 (1988). To be upheld, a classification analyzed under the 
intermediate level of scrutiny must be substantially related to an important governmental objective. 
See id. 
270. 481 F. Supp. at 203. 
271. See id. at 225. 
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those conditions and an opportunity for higher eamings.272 These circumstances 
suggest that the prisoners might have enrolled in the clinical trials not because 
they wished to participate in the biomedical research and understood its purpose 
and implications, but solely because they hoped to escape some of the intolerable 
prison conditions. Prisoners who underwent experimentation for which they did 
not provide meaningful consent arguably suffered a violation of their right to 
bodily integrity or liberty. Nevertheless, considering all the evidence in the case 
and the informed consent provided by participants, the court found that the 
inclusion of inmates in the medical experiments at issue did not "shock the 
conscience" or defy constitutional standards.Z73 
On the other hand, prisoners who desire access to experimental treatment and 
are denied permission to participate in a clinical trial may be able to establish that 
their exclusion from therapeutic medical research violates the Fourteenth 
Amendment. Although federal law permits the inclusion of prisoners in c1 inical 
trials in limited circumstances, state laws and correctional policies continue to 
prohibit prisoners' access to biomedical studies in many jurisdictions.274 
Prisoners may challenge state laws or regulations barring access to clinical trials 
by asserting that the state action violates the due process and equal protection 
clauses of the Fourteenth Amendment. They may contend that the state is 
depriving them of the liberty to enjoy the benefits of clinical research or is 
endangering their lives if it is precluding access to potentially life-saving 
treatment. Likewise, they may argue that they are subjected to unequal treatment 
based on their status as prisoners. 
InFante v. Department of Health and Human Services, 275 prisoners from the 
State Prison of Southern Michigan at Jackson challenged proposed FDA 
regulations limiting prisoner access to clinical trials on due process and equal 
protection grounds?76 Cecil Cone, an inmate who had volunteered to participate 
in trials involving radioactive tracers, tuberculosis tests, medicated skin lotions, 
and antacids, stated that he wished to continue participating in nontherapeutic 
studies because they relieved the sheer boredom of prison life and allowed him 
to supplement his meager prison income.277 The drug testing, according to Cone, 
provided "a change of pace. It's like a little vacation."278 In addition, the money 
provided a powerful incentive.279 The FDA apparently found the prisoners' 
arguments to be compelling because it withdrew its proposed regulations and 
272. Seeid.at219. 
273. See id. 
274. See Kelly, supra note 131, at 58. 
275. Civil Action No. 80-727788 (E.D. Mich. filed July 29, 1980), cited in 46 Fed. Reg. 
35085 (1981). 
276. See Schroeder, supra note 3, at 986. 
277. See Marjorie Sun, Inmates Sue to Keep Research in Prisons, 212 SCIENCE 650, 650 
(May 8, 1981). 
278. /d. 
279. See id. 
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never reissued a different proposal.280 However, no court decision was issued 
regarding the question of the prisoners' constitutional rights. 
The prisoners in the Fante case argued that the proposed FDA regulations 
would deprive them of the liberty to enjoy the benefits of clinical research 
without due process of law and that they were denied the equal protection of the 
law because of their status as prisoners.281 Seriously ill prisoners seeking 
participation in clinical trials for medical reasons rather than for income or a 
break from routine would have a far more persuasive argument than did the 
Fante plaintiffs and may well be able to prevail in a court action. 
It must be noted, however, that it will be difficult to establish the existence 
of a fundamental right of access to clinical trials for incarcerated individuals. 
Although prisoners have a constitutional right to receive medical care in 
prison, 282 no court has deemed this fundamental right to extend to 
nonconventional, experimental treatments. In addition, prisoners are not among 
the identified suspect classes and thus are not entitled to heightened scrutiny 
under the Equal Protection Clause.283 State laws or correctional policies 
prohibiting the participation of prisoners in biomedical studies would therefore 
be analyzed under the rational basis test. 
In defending a Fourteenth Amendment claim, the state would presumably 
argue that its reason for precluding prisoners from involvement in biomedical 
research is to protect them from coerced or uninformed participation or from the 
abuses of irresponsible research. As discussed above, however, existing federal 
regulations provide numerous safeguards against research abuses so long as they 
are conscientiously implemented by IRBs.284 The regulations mandate that 
prisoners can participate only in studies that will directly benefit the subject or 
the inmate population in general and prohibit prisoner involvement in 
nontherapeutic clinical trials.285 Moreover, the regulations implement safeguards 
relating to IRB review, selection of subjects, informed consent, and the 
performance of the experimentation.286 In light of these extensive federal 
regulations, it will be difficult for the state to establish that a complete ban on 
prisoner studies, including those with life-saving potential, bears a rational 
relationship to the goal of providing prisoners with meaningful protection.287 A 
state law or policy barring prisoner access to potentially life-saving experimental 
therapy may consequently be revoked even under Due Process or Equal 
Protection "rational basis" scrutiny. 
280. See Kelly, supra note 131, at 56. 
281. See Sun, supra note 277, at 650. 
282. See Estelle v. Gamble, 429 U.S. 97, 103 (1976). 
283. See Cleburne v. Cleburne Living Ctr., Inc., 473 U.S. 432, 440 (1985). 
284. See discussion supra Part III. 
285. See 45 C.F.R. § 46.306 (1998). 
286. See id. §§ 46.304, 46.305. 
287. If the state argues that its ban is motivated by concerns about cost and security, these 
arguments too will prove weak and could be defeated under the rational basis test. See discussion 
supra Part IV. 
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It is tempting to assert an Equal Protection argument based on the reality that 
minorities are disproportionately affected by bans on studies involving prisoners. 
This argument, however, is destined to fail. 
Scholars have noted that African Americans and Hispanics constitute a 
disproportionately large percentage of the prison population, compared to their 
general population rates.288 African Americans make up approximately half of 
the United States' 1.8 prison population, and Hispanics account for fifteen 
percent, while only twelve percent of the U.S. population is Black, and eleven 
percent is Hispanic.289 AIDS and other diseases also affect African Americans 
and Hispanics disproportionately.290 As of June 1994, fifty percent of all AIDS 
patients were Black or Hispanic. 291 By 1998 Blacks accounted for forty-nine 
percent of AIDS deaths, and eighteen percent of AIDS deaths were among 
Hispanics.292 Black men have a higher risk of cancer and cirrhosis of the liver 
than non-African American men, and Hispanics report higher rates of heart 
disease, cancer, and chronic liver disease than do non-Hispanics.293 
No constitutional claim can be based on these statistics. The Constitution 
prohibits only purposeful discrimination, and facially neutral governmental 
actions cannot be constitutionally challenged using a disparate impact theory.294 
Nevertheless, the fact that minorities are disproportionately affected by both 
imprisonment and particular diseases, provides a compelling reason for the 
inclusion of inmates in clinical studies, as will be discussed in Part V.A below. 
2. The Right to Privacy.-The constitutional right to privacy is somewhat 
amorphous and may be rooted in a variety of provisions.295 The right to privacy 
has been described most often as stemming from the Fourteenth Amendment's 
concept ofpersonalliberty.296 It may also be found in the Ninth Amendment's 
reservation of rights to the people.297 In Griswoldv. Connecticut,298 the Supreme 
Court determined that "the First Amendment has a penumbra where privacy is 
protected from governmental intrusion."299 The right to privacy also includes the 
right to be free from governmental surveillance and intrusion in one's private 
affairs, which stems from the Fourth Amendment.300 
288. See Kelly, supra note 131, at 51. 
289. See Michael A. Fletcher, The Crime Conundrum; Policing Is Tougher, Jails Fuller, and 
Crime Is at a 30-Year Low, WASH. POST, Jan. 16, 2000, at Fl; Shapiro, supra note 16, at 2A. 
290. See Fletcher, supra note 289, at Fl; Shapiro, supra note 16, at 2A. 
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292. See Karen Gullo, Clinton to Seek AIDS Funds, AP ONLINE, Jan. 18, 2000 (citing CDC 
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293. See Marquart et al., supra note 208, at 188. 
294. See Washington v. Davis, 426 U.S. 229 (1976). 
295. See Whalen v. Roe, 429 U.S. 589, 598-99 nn.23-25 (1977). 
296. See id. n.23 (citing Roe v. Wade, 410 U.S. 110, 153 (1973)). 
297. See id. 
298. 381 U.S. 479 (1965). 
299. !d. at 483. 
300. See Whalen, 429 U.S. at 599 n.25. 
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The right to privacy generally encompasses the right to maintain 
confidentiality regarding medical information, and some courts have held that 
even prisoners enjoy this right, particularly with respect to HIV status.301 Other 
courts have found, however, that inmates do not retain a constitutional right to 
the confidentiality of their medical records.302 Prisoners do, nonetheless, have 
a restricted constitutional right to bodily privacy.303 
The Bailey04 court only briefly addressed the privacy issue. It found the 
plaintiffs' privacy claims to be unfounded because the prisoners volunteered for 
the experimental procedures at issue and were not subjected to involuntary 
treatment as was the case in the precedents they cited.305 Likewise, under 
contemporary regulatory guidelines, prisoner enrollment cannot be coerced. 
Thus, it is highly unlikely that biomedical research will give rise to violation of 
constitutional privacy rights. 
A related but different claim may arise from the Fourth Amendment, which 
establishes "[t]he right of the people to be secure ... against unreasonable 
searches and seizures."306 Invasive medical procedures, such as blood tests, can 
constitute searches and seizures that impinge upon the constitutional rights of the 
patient, even in the prison context.307 The Bailey court did not address any 
potential search and seizure claims. Nevertheless, if bodily fluids are extracted 
from prisoners who have not provided informed consent, Fourth Amendment 
violations may arise. Clinical studies that comply with DHHS regulations 
requiring voluntariness and informed consent, however, should not infringe upon 
any participant's right to be free of unreasonable searches and seizures. 
If prisoners provide genuine informed consent to biomedical 
experimentation, if the study is thoroughly reviewed by an IRB, and if the 
research conforms to the guidelines of federal regulations, then sufficient 
safeguards will be implemented to assure that the subjects' rights to bodily 
integrity and privacy will not be sacrificed. Nevertheless, a significant concern 
exists that adequate confidentiality regarding medical records may not be 
maintained in the prison setting. The DHHS regulations governing research 
involving inmates do not address the issue of confidentiality.308 As discussed 
below, precautions must be taken to assure confidentiality for inmate 
participants. 
301. See, e.g., Harris v. Thigpen, 941 F.2d 1495, 1513 (11th Cir. 1991); Clarkson v. 
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Constitutional concerns do not justify the exclusion of prisoners from 
medical research. It is arguable that the Eighth and Fourteenth Amendments 
mandate the provision oflife saving therapy to seriously ill prisoners even if the 
treatment is available only through a clinical trial. While inmate participation in 
clinical trials may be hampered by certain practical hurdles, these obstacles are 
not insurmountable, as demonstrated by several programs that successfully 
integrate prisoners into research protocols.309 The following section will discuss 
the experience of medical institutions that include prisoners in therapeutic 
clinical studies and will outline recommendations to facilitate the implementation 
of such programs. 
V. POLICY ISSUES AND RECOMMENDATIONS 
A. Several Jurisdictions Recognize the Importance of Including 
Prisoners in Clinical Trials 
In July 1995 the New Jersey Community Research Initiative issued a report 
entitled Prisoners with HIV· Guidelines for Implementing Clinical Trials in 
Correctional Settings .310 The report found that"[ m ]any leaders in medical ethics 
have concluded that the coercive nature of correctional settings should not 
prevent prisoners from participating in medically appropriate clinical studies. "311 
It cited the findings of a 1989 consensus panel of leaders in corrections, prison 
health care, and public health that likewise found that "although a prison setting 
precludes the voluntary and uncoerced choice classically envisioned by the 
federal regulations, prisoners should be permitted to choose to participate in 
therapeutic trials . . . that hold out the possibility of benefit. "312 The report 
further noted that "public health officials, including the World Health 
Organization and the former National Commission on AIDS, have advocated 
prisoner access to clinical research."313 
Including prisoners in biomedical studies is important for reasons that go 
beyond benefits to the subjects themselves. Traditionally, African Americans, 
Hispanics, intravenous drug users, and women have been underrepresented in 
clinical trials. 314 Two important studies in which AZT was tested were 
conducted with a population that was more than ninety-two percent White and 
male.315 A 1991 report produced by the AIDS Clinical Trial Group concluded 
that African Americans made up only ten percent of participants in this national 
consortium of clinical trials, Hispanics twelve percent, and IV drug users and 
309. See Kelly, supra note 131, at 60. 
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women accounted for eleven percent and six percent, respectively.316 
Researchers have found that members of different races at times respond to 
treatments in different ways.317 Whites and Blacks, for example, respond 
differently to hypertensive therapy. 318 Women may respond differently from men 
because of variations in size, body fat, and hormonal levels.319 Similarly, the 
efficacy of drugs may be significantly affected by other drugs, including illegal 
substances taken by the patient.320 Exclusion of minority subjects from drug 
studies is thus "bad science" and will adversely impact both the researcher and 
future patients.321 The prison environment provides a diverse population, with 
a high concentration of minorities. Allowing prisoners to participate in 
therapeutic clinical studies will benefit not only the inmate patients, but also the 
medical community and society at large. 
Research institutions in several states have succeeded in integrating prisoners 
into clinical trials. In Texas, Virginia, and New York research entities provided 
standard medical care to prisoners before establishing programs that included 
inmates in clinical studies.322 In Texas, the University of Texas Medical Branch 
at Galveston ("UTMB") has served as the primary prison hospital for the Texas 
Department of Criminal Justice ("TDCJ") since 1983.323 It is staffed by security 
personnel who report to TDCJ and health care professionals who answer to the 
University.324 For many years, Texas inmates have been enrolled in clinical trials 
involving protocols that may be of direct benefit to them. 325 Historically, the 
majority of the studies at UTMB in which prisoners have been included have 
been cancer-related, but an increasing number in recent years have focused on 
AIDS treatment. 326 
In New York City, the Spellman Center for HIV-Related Disease at St. 
Clare's Hospital has provided care to many HIV -infected New York inmates and 
involved prisoners in clinical trials for several years beginning in 1986.327 In 
Albany, New York, Albany Medical College provides hospital care for prisoners 
in twenty-five correctional facilities. 328 The facility began enrolling prisoners in 
AIDS-related trials in 1988 and included inmates in oncologic clinical trials in 
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318. See id. 
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prior years.329 The Division of Infectious Diseases at the Medical College of 
Virginia has served the Virginia state prison population since 1985 and has 
enrolled prisoners in clinical trials since 1990.330 
Not all research institutions that include inmates in medical studies provide 
healthcare services to prisoners outside of clinical trials.331 Johns Hopkins 
University in Maryland has established several AIDS-related clinical trials in 
Maryland prisons since 1991, although it is not otherwise a provider of treatment 
for Maryland prisoners.332 In Colorado, the Department of Health has also 
allowed prisoner participation in AIDS-related trials. 333 Likewise, Yale 
University Medical School has worked with prisoners in medical research 
studies. 334 
B. The Challenges of Prisoner Involvement in Clinical Trials 
The commentators who advocate the inclusion of prisoners in clinical studies 
recognize the existence of certain obstacles inherent to the prison setting.335 
Nevertheless, the obstacles are not insurmountable, as evidenced by the fact that 
research is successfully conducted by some institutions, as discussed above. 
1. Confidentiality.-Prisoners participating in AIDS-related clinical trials 
risk disclosure of their HIV status either because it is obvious that they are 
receiving frequent and specialized medical care or because ofthe prison's record-
keeping policies.336 Disclosure ofillV status may be particularly dangerous for 
inmates because of the risk that other prisoners or correctional officers will 
subject the patient to persecution and violence.337 
The Forum on Prisoner Access to Clinical Trials in New Jersey 
acknowledged that maintaining fully effective confidentiality in the prison setting 
is nearly impossible.338 However, it suggested several alternatives to safeguard 
the privacy of research participants. Although it is not clear that prisoners retain 
a right to confidentiality regarding HIV status, 339 every effort should be made to 
prevent disclosure ofinmates' receipt ofHIV -related experimental therapy. Such 
precautions will safeguard the prisoners' constitutional rights to the extent they 
exist, will encourage inmates to participate in clinical trials, and will reduce 
prisoner grievances and litigation regarding confidentiality matters. Where the 
research institution provides routine medical care to inmates and frequently sends 
329. See id at 60-61. 
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331. See id. 
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staff to the correctional facility, it is easiest to maintain confidentiality for 
clinical trial enrollees. Inmates should be allowed to communicate directly with 
investigators about clinical trials without having to request permission from 
prison officials. 340 Investigators could publicize the research through newsletters 
or postings that are seen by all inmates. Enrollment could then occur during a 
routine medical visit by the institution's staff rather than on a day specifically 
designated for discussion of the AIDS-related study.341 
Moreover, the Forum on Prisoner Access to Clinical Trials recommends that 
medical records that contain information about HIV status be maintained in 
secured areas that can be accessed only by medical personnel directly responsible 
for the inmate's treatment. 342 Correctional officers and other inmates should not 
have access to sensitive medical records even if they are assigned to work in the 
prison's medical department. 343 
Finally, the Forum suggests that prisoners also have confidential access to 
investigators in the event that they suffer adverse side effects from 
investigational drugs.344 Prisoners involved in clinical trials should be allowed 
to place collect calls to designated medical personnel or to an answering service 
twenty-four hours a day.345 In Maryland, investigators are available by beeper 
around the clock.346 Where telephone usage by prisoners is restricted, however, 
inmates may be limited to reaching research staff through prison medical 
personnel and thus may be forced to disclose confidential information to 
correctional officials.347 
2. Logistics and Communication.-Transportation issues may constitute 
another hurdle to prisoner participation in biomedical research. 348 Where studies 
are conducted in correctional facilities, researchers must travel to prison clinics, 
bringing with them all necessary medical equipment and carrying out of the 
prison bodily fluid samples for testing.349 They must also undergo time-
consuming security checks each time they arrive at the prison. 350 Where clinical 
trials are conducted on hospital grounds, prisoners must be transported under 
guard to and from the hospital. Significant delays are often caused by prison 
lockdowns, inmate counts, and other security precautions.351 
Restrictions on items that can be possessed by prisoners may also be 
problematic for clinical research purposes. Since bottles and pills are contraband 
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in most prisons, procedures must be implemented to allow prisoners to keep 
experimental drugs with them or to have them administered in a manner that 
maintains confidentiality.352 In some New Jersey jails prisoners have a self-
dosing system for their prescription medications that features locked boxes.353 
A similar mechanism could be implemented in other prisons, though correctional 
officers would have to be educated to maintain confidentiality regarding the 
nature of prisoners' medications and any modifications of general prison policies 
that apply to clinical trial participants.354 
Another problem may arise in instances where prisoners are transferred from 
one facility to another. 355 Inmates should be able to continue receiving the 
experimental treatment at the new facility.356 A "medical hold" could be placed 
on trial participants designated for relocation so that the central administration, 
in consultation with medical investigators, may evaluate whether the transfer will 
cause any adverse consequences to the patient or the research study. 357 Thus, 
prison administrators will avoid potential violation of the inmates' Eighth 
Amendment right to adequate medical care and will not jeopardize the prisoners' 
health by sudden and unmonitored discontinuation of experimental treatment. 
Similarly, continuity of care should be assured for prisoners who are paroled 
or released.358 In Maryland, a research nurse meets with the prisoner prior to 
release and encourages the individual to continue trial participation once 
released.359 Researchers should offer former prisoners assistance with 
transportation to and from the research site and work with parole officers to 
assure appropriate sustained treatment. 360 
A recent statement issued by the Office of the Inspector General of the U.S. 
Department of Health and Human Services is highly critical of the institutional 
review board system.361 It noted that a "1995 Advisory Commission on Human 
Radiation Experiments found in their interviews with actual research subjects 
that few realized they were participants in research and many had little 
understanding of the informed consent forms they signed. "362 The statement 
further denounced the limited continuing review conducted by most IRBs that, 
burdened by ever-increasing workloads, do no more than review paperwork 
submitted by research investigators and fail to solicit feedback from research 
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subjects.363 The Office of the Inspector General also urged research institutions 
to provide adequate education for IRB members concerning ethical issues and 
scientific questions and noted that currently IRB training is minimal to 
nonexistent. 364 
As discussed throughoutthis Article, IRBs approving clinical trials involving 
prisoners must meet stringent requirements that are inapplicable to reviews of 
other studies. The IRB must include a prisoner advocate, review the proposed 
study in light of guidelines specific to the prison setting, and provide prisoners 
with data presented in language that they can understand.365 IRBs are therefore 
likely to review protocols involving prisoners more meticulously than they might 
review other research proposals. Nevertheless, the comments of the Office of 
Inspector General are prudent admonitions for anyone reviewing research 
protocols designed to include prisoner participants. IRBs should be well versed 
in the ethical dilemmas that are potentially involved in prisoner research, must 
ensure that meaningful informed consent is obtained, and should conduct 
thorough and conscientious continuing reviews of the clinical trials in question. 
CONCLUSION 
Although federal regulations permit the inclusion of prisoners in therapeutic 
clinical trials from which they may gain direct treatment benefits, prisoners are 
able to enroll in clinical trials in only a few locations.366 Although perhaps well-
intentioned, policies that ban the inclusion of inmates in biomedical studies are 
detrimental to prisoners, to science, and to society at large because they preclude 
research utilizing a particularly diverse and disadvantaged segment of society. 
In the words of Justice Brandeis: 
Experience should teach us to be most on our guard to protect liberty 
when the Government's purposes are beneficent. Men born to freedom 
are naturally alert to repel invasion of their liberty by evil-minded rulers. 
The greatest dangers to liberty lurk in insidious encroachment by men of 
zeal, well-meaning but without understanding.367 
Clinical trials that comply with federal regulations will not violate any of the 
participants' constitutional rights. In Bailey v. Lally,368 the court found no 
constitutional violations despite extremely harsh prison conditions that often 
motivated prisoner participation in research studies that were nontherapeutic and 
had not been scrutinized by a reviewing entity such as an IRB?69 In light of 
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364. See id. at 11-12. 
365. See 45 C.F.R. §§ 46.304-46.306 (1998). 
366. See Kelly, supra note 131, at 58. 
367. Olmstead v. United States, 277 U.S. 438, 479 (1928) (Brandeis, J., dissenting). 
368. 481 F. Supp. 203 (D. Md. 1979). 
369. See id. 
2000] PRISONER PARTICIPATION IN CLINICAL TRIALS 515 
contemporary regulations, it is difficult to imagine that any subsequent court 
would deem voluntary participation in therapeutic studies to impinge upon the 
constitutional rights of an enrollee. 
The exclusion of seriously ill prisoners from clinical trials through which 
they may receive potentially life-saving treatment is constitutionally dubious and 
morally troubling. It is arguable that prisoners have a right to participation under 
the Eighth Amendment, the Due Process clause, and the promise of Equal 
Protection. In addition, moral considerations impel the allowance of prisoner 
enrollment in therapeutic biomedical research. Two commentators have 
summarized the arguments well: 
Inmates as a group ... need to be provided with access to clinical trials 
of new and innovative therapies that present the possibility of direct 
benefit. . . . They must be presented with the opportunity for informed 
choice when appropriate, despite recognition that the systematic 
deprivations and inherent coerciveness of the institutions and the 
desperate character of HIV infection compromise the consent process. 
As in other areas of public policy and public health, HIV infection 
demands a fresh examination of equity and justice. Whether access is 
provided to promising investigational therapies will measure the mettle, 
courage, inventiveness, and flexibility of the medical research 
community. It will also test the humanity of correctional administrators, 
who must provide the setting and support services to permit the conduct 
and monitoring of clinical trials.370 
Policy makers, legislators, and prison authorities must meet the challenge of 
providing appropriate treatment for seriously ill prisoners, including that which 
is available through experimental protocols. To fail to do so would defy the 
"broad and idealistic concepts of dignity, civilized standards, humanity, and 
decency"371 embodied in the Constitution and in American jurisprudence. 
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